The 16th iteration of the Clinical Trials in Alzheimer’s Disease conference, held October 24-27 in Boston, drew some 2,300 participants, of whom 1,500 crowded into a downtown hotel for the in-person experience while 800 followed proceedings remotely. The meeting started with a session on how efforts to diversify research participation in trials are beginning to yield data on biomarker positivity among different groups, and continued with a focus on which patients might benefit most from amyloid reduction.